---
title: "Nomura raises HANSOH PHARMA's target price to 37.87 yuan, upgrading revenue and earnings estimates"
description: "Nomura has raised the target price for HANSOH PHARMA to RMB 37.87, expecting a 10% growth in both revenue and profit for the fiscal year 2026. Revenue in the second half of 2025 is expected to grow by"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276027718.md"
published_at: "2026-02-16T03:03:41.000Z"
---

# Nomura raises HANSOH PHARMA's target price to 37.87 yuan, upgrading revenue and earnings estimates

> Nomura has raised the target price for HANSOH PHARMA to RMB 37.87, expecting a 10% growth in both revenue and profit for the fiscal year 2026. Revenue in the second half of 2025 is expected to grow by 27% to RMB 7.3 billion, with drug sales increasing by 17% to RMB 6.6 billion and collaboration revenue at RMB 743 million. The gross margin is expected to be 91.6%, and the operating profit margin is 26.9%. It is anticipated that the net profit attributable to shareholders in the second half of 2025 will be RMB 2.1 billion, an increase of 29.4%. At the same time, the revenue and profit forecasts for the fiscal year 2025 have been raised by 1% and 4.7%, respectively, maintaining a "Neutral" rating

Nomura published a research report indicating that HANSOH PHARMA (03692.HK) is expected to achieve a 10% growth in both revenue and profit for the fiscal year 2026. The firm anticipates that HANSOH's revenue in the second half of 2025 will grow by 27% year-on-year to RMB 7.3 billion, slightly higher than the market consensus forecast, which includes a 17% year-on-year increase in drug sales to RMB 6.6 billion, as well as confirmed collaboration revenue of RMB 743 million.

The firm’s forecast takes into account the continued growth in sales of oncology and anti-infection drugs, as well as collaboration with Regeneron Pharmaceuticals. Nomura expects HANSOH PHARMA's profit margins to improve in the second half of 2025, with a gross margin of 91.6% (an increase of 0.8 percentage points year-on-year) and an operating margin of 26.9% (an increase of 3.9 percentage points year-on-year). Overall, the firm expects HANSOH's net profit attributable to shareholders in the second half of 2025 to be RMB 2.1 billion, representing a year-on-year growth of 29.4%.

Nomura has raised its revenue and profit forecasts for the fiscal year 2025 by 1% and 4.7%, respectively, to account for higher collaboration revenue. The firm has increased its target price from RMB 35.5 to RMB 37.87 and maintains a "Neutral" rating

### Related Stocks

- [03692.HK - HANSOH PHARMA](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 翰森制药宣布，甲磺酸奥莫替尼片在欧盟获批用于单药治疗 | 汉森制药集团有限公司：AUMOLERTINIB 美克替尼片在欧盟作为单药治疗获得批准 | [Link](https://longbridge.com/en/news/276401882.md) |
| 翰森制药集团有限公司宣布其单药疗法在欧盟获得批准 | 汉森制药集团有限公司宣布，阿莫雷替尼美克沙片（在中国称为 Ameile）获得欧盟批准，作为单药治疗用于治疗晚期非小细胞肺癌（NSCLC）。这包括针对特定 EGFR 突变的成人患者的首选治疗，以及针对 EGFR T790M 突变阳性 NSCL | [Link](https://longbridge.com/en/news/276480305.md) |
| 贝森特和沃什的 “导师”，德鲁肯米勒 Q4“精准” 开仓金融股 ETF、标普等权重 ETF 和巴西 ETF | 科技股方面，德鲁肯米勒 Q4 清仓了 Meta，加仓了谷歌与 Sea。德鲁肯米勒与贝森特、沃什的 “师徒” 关系让市场推测，“德鲁肯米勒经济学”——即反赤字、反通胀、反关税——可能通过贝森特和沃什渗透至政策制定中。 | [Link](https://longbridge.com/en/news/276214511.md) |
| 特朗普暗示违法征收的关税不退了，美财长称今年关税收入将 “基本保持不变” | 美国总统特朗普暗示不会退还被最高法院裁定违法的关税，预计 2026 年关税收入将保持不变。特朗普计划签署行政令，对全球商品加征 10% 进口关税，取代被推翻的关税。财长贝森特表示，政府将利用替代法律权力维持关税收入，强调国家安全和财政收入不 | [Link](https://longbridge.com/en/news/276494362.md) |
| 翰森制药的关键肺癌药物奥莫替尼获得欧盟批准 | 翰森制药获得欧盟对关键肺癌药物阿莫雷替尼的批准 | [Link](https://longbridge.com/en/news/276393466.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.